Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer

Reference

• Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693 - 703; http://dx.doi.org/10.1056/NEJMoa1006448; PMID: 20979469
   PubMed Web of Science ®Google Scholar
• Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, et al. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol 2010; 5:2044 - 6; http://dx.doi.org/10.1097/JTO.0b013e318200f9ff; PMID: 21102269
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12:1004 - 12; http://dx.doi.org/10.1016/S1470-2045(11)70232-7; PMID: 21933749
   PubMed Web of Science ®Google Scholar
• Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol 2013; 31:1105 - 11; http://dx.doi.org/10.1200/JCO.2012.44.5353; PMID: 23401436
   PubMed Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012; 4:20ra17; http://dx.doi.org/10.1126/scitranslmed.3003316; PMID: 22277784
   PubMed Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, et al, ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363:1734 - 9; http://dx.doi.org/10.1056/NEJMoa1007478; PMID: 20979473
   PubMed Web of Science ®Google Scholar
• Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011; 71:6051 - 60; http://dx.doi.org/10.1158/0008-5472.CAN-11-1340; PMID: 21791641
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res 2012; 18:6219 - 26; http://dx.doi.org/10.1158/1078-0432.CCR-12-0392; PMID: 22843788
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18:1472 - 82; http://dx.doi.org/10.1158/1078-0432.CCR-11-2906; PMID: 22235099
   PubMed Web of Science ®Google Scholar
• Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 2011; 108:7535 - 40; http://dx.doi.org/10.1073/pnas.1019559108; PMID: 21502504
   PubMed Web of Science ®Google Scholar
• Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, et al. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res 2012; 18:3592 - 602; http://dx.doi.org/10.1158/1078-0432.CCR-11-2972; PMID: 22553343
   PubMed Web of Science ®Google Scholar
• Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 2013; 3:430 - 43; http://dx.doi.org/10.1158/2159-8290.CD-12-0440; PMID: 23533265
   PubMed Web of Science ®Google Scholar
• Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14:4275 - 83; http://dx.doi.org/10.1158/1078-0432.CCR-08-0168; PMID: 18594010
   PubMed Web of Science ®Google Scholar
• Takezawa K, Okamoto I, Nishio K, Jänne PA, Nakagawa K. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin Cancer Res 2011; 17:2140 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-10-2798; PMID: 21415216
   PubMed Web of Science ®Google Scholar
• McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008; 68:3389 - 95; http://dx.doi.org/10.1158/0008-5472.CAN-07-6186; PMID: 18451166
   PubMed Web of Science ®Google Scholar
• Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene 2007; 26:5606 - 14; http://dx.doi.org/10.1038/sj.onc.1210346; PMID: 17353907
   PubMed Web of Science ®Google Scholar
• Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 2013; 13:685 - 700; http://dx.doi.org/10.1038/nrc3580; PMID: 24060861
   PubMed Web of Science ®Google Scholar
• Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 2011; 8:528 - 39; http://dx.doi.org/10.1038/nrclinonc.2011.71; PMID: 21587219
   PubMed Web of Science ®Google Scholar
• Cheng Y, Qiu F, Tashiro S, Onodera S, Ikejima T. ERK and JNK mediate TNFalpha-induced p53 activation in apoptotic and autophagic L929 cell death. Biochem Biophys Res Commun 2008; 376:483 - 8; http://dx.doi.org/10.1016/j.bbrc.2008.09.018; PMID: 18796294
   PubMed Web of Science ®Google Scholar
• Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence. FEBS J 2010; 277:2 - 21; http://dx.doi.org/10.1111/j.1742-4658.2009.07366.x; PMID: 19843174
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ren X, Hait WN, Yang JM. Therapeutic targeting of autophagy in disease: biology and pharmacology. Pharmacol Rev 2013; 65:1162 - 97; http://dx.doi.org/10.1124/pr.112.007120; PMID: 23943849
   PubMed Web of Science ®Google Scholar
• Shingu T, Fujiwara K, Bögler O, Akiyama Y, Moritake K, Shinojima N, Tamada Y, Yokoyama T, Kondo S. Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells. Int J Cancer 2009; 124:1060 - 71; http://dx.doi.org/10.1002/ijc.24030; PMID: 19048625
   PubMed Web of Science ®Google Scholar
• Degtyarev M, De Mazière A, Orr C, Lin J, Lee BB, Tien JY, Prior WW, van Dijk S, Wu H, Gray DC, et al. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol 2008; 183:101 - 16; http://dx.doi.org/10.1083/jcb.200801099; PMID: 18838554
   PubMed Web of Science ®Google Scholar